EUVIMEDEUVIMED entdecken
Vergleichsstudie

Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes

Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron, Christina Shay, Keith Marsolo, Raj C Shah, W Schuyler Jones, Howard Gordon, Wenke Hwang, Isabelle Ayoub und 11 weitere

JACC · 2024-08 · 84 (8) · 696-708

DOI: 10.1016/j.jacc.2024.06.016 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JACC, 2024-08. Verfasst von Daniel Edmonston und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Du…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glomerular Filtration Rate, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Boehringer Ingelheim Corp USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors (SGLT2i), a first-line therapy for this population, are needed. OBJECTIVES: The authors compared kidney and cardiovascular outcomes for new users of SGLT2i and GLP-1 RAs with T2D. METHODS: Using propensity score overlap weighting, we analyzed electronic health record data from 20 U.S. health systems contributing to PCORnet between 2015 and 2020. The primary kidney outcome was a composite of sustained 40% estimated glomerular filtration rate (eGFR) decline, incident end-stage kidney disease, or all-cause mortality over 2 years or until censoring. In addition, we examined cardiovascular and safety outcomes. RESULTS: The weighted study cohort included 35,004 SGLT2i and 47,268 GLP-1 RA initiators. Over a median of 1.2 years, the primary outcome did not differ between treatments (HR: 0.91; 95% CI: 0.81-1.02), although SGLT2i were associated with a lower risk of 40% eGFR decline (HR: 0.77; 95% CI: 0.65-0.91). Risks of mortality (HR: 1.08; 95% CI: 0.92-1.27), a composite of stroke, myocardial infarction, or death (HR: 1.03; 95% CI: 0.93-1.14), and heart failure hospitalization (HR: 0.95; 95% CI: 0.80-1.13) did not differ. Genital mycotic infections were more common for SGLT2i initiators, but other safety outcomes did not differ. The results were similar regardless of chronic kidney disease status. CONCLUSIONS: SGLT2i and GLP-1 RAs led to similar kidney and cardiovascular outcomes in people with T2D, though SGLT2i initiation was associated with a lower risk of 40% eGFR decline. (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease; NCT05465317).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlomerular Filtration RateGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedAgedCardiovascular DiseasesHypoglycemic AgentsKidney Failure, Chronic

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney diseasediabetes mellitusglucagon-like 1 receptor agonistssodium-glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA. Electron…
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA.
  • Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Family and Preventive Medicine and the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
  • Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Förderung

  • Boehringer Ingelheim Corp USA

Zitieren

APA

Edmonston, D., Mulder, H., Lydon, E., Chiswell, K., Lampron, Z., Shay, C., Marsolo, K., Shah, R. C., Jones, W. S., Gordon, H., Hwang, W., Ayoub, I., Ford, D., Chamberlain, A., Rao, A., Fonseca, V., Chang, A., Ahmad, F., Hung, A., …, & Pagidipati, N. (2024). Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC, 84(8), 696-708. https://doi.org/10.1016/j.jacc.2024.06.016

Vancouver

Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, et al. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC. 2024;84(8):696-708. doi:10.1016/j.jacc.2024.06.016

BibTeX
@article{Edmonston2024,
  author = {Edmonston, Daniel and Mulder, Hillary and Lydon, Elizabeth and Chiswell, Karen and Lampron, Zachary and Shay, Christina and Marsolo, Keith and Shah, Raj C and Jones, W Schuyler and Gordon, Howard and Hwang, Wenke and Ayoub, Isabelle and Ford, Daniel and Chamberlain, Alanna and Rao, Ajaykumar and Fonseca, Vivian and Chang, Alexander and Ahmad, Faraz and Hung, Adriana and Hunt, Kelly and Butler, Javed and Bosworth, Hayden B and Pagidipati, Neha},
  title = {Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes},
  journal = {JACC},
  year = {2024},
  volume = {84},
  number = {8},
  pages = {696--708},
  doi = {10.1016/j.jacc.2024.06.016}
}
Kostenlos starten →